title: Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry.
abstract: Type I collagen makes up more than 90% of bone matrix. Therefore, analysis of antigens related to collagen formation and degradation in bone should provide good and specific estimates of both bone resorption and bone formation rates. In this study we measured serum levels of the pyridinoline cross-linked telopeptide domain of type I collagen (ICTP) as a marker of bone resorption and serum carboxy-terminal propeptide of type I procollagen (PICP) as a marker of bone formation. Serum levels of the two antigens were correlated to histomorphometric indices of bone resorption and bone formation calculated from iliac crest bone biopsies in a group of 18 individuals with high- and low-turnover bone disease (myxedema, primary hyperparathyroidism, and thyrotoxicosis). After logarithmic transformation the regression of S-ICTP on volume-referent resorption rate (BRs/R/BV) was significant (r = 0.61, p < 0.01, SEM/Y = 56%). S-ICTP also showed a significant regression on the volume-referent cancellous bone balance (r = -0.45, p < 0.05, SEM/Y = 412%). S-PICP was significantly correlated to the mineral appositional rate (r = 0.53, p < 0.05) and volume-referent bone formation rate (r = 0.61, p < 0.01, SEM/Y = 48%). The correlation to bone turnover as expressed in the activation frequency was also highly significant (r = 0.61, p < 0.01, SEM/Y = 51%). No significant correlation with wall thickness or bone balance was demonstrable per remodeling cycle. Thus, assays employing antigens that reflect collagen formation and degradation are useful instruments for the evaluation of rates of bone remodeling in metabolic bone disease.
authors.affiliation: University Department of Endocrinology and Metabolism, Aarhus Amtssygehus, Denmark.
authors.forename: E F
authors.initials: EF
authors.lastname: Eriksen
authors.forename: P
authors.initials: P
authors.lastname: Charles
authors.forename: F
authors.initials: F
authors.lastname: Melsen
authors.forename: L
authors.initials: L
authors.lastname: Mosekilde
authors.forename: L
authors.initials: L
authors.lastname: Risteli
authors.forename: J
authors.initials: J
authors.lastname: Risteli
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D001846:Bone Development; D001851:Bone Diseases, Metabolic / Q000097:blood* / Q000473:pathology / Q000503:physiopathology; D001862:Bone Resorption; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology*; D003094:Collagen / Q000378:metabolism*; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood / Q000473:pathology / Q000503:physiopathology; D007085:Ilium; D008297:Male; D008875:Middle Aged; D009230:Myxedema / Q000097:blood / Q000473:pathology / Q000503:physiopathology; D010446:Peptide Fragments / Q000097:blood*; D010455:Peptides / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D012044:Regression Analysis; D013971:Thyrotoxicosis / Q000097:blood / Q000473:pathology / Q000503:physiopathology
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C042813:procollagen type I carboxy terminal peptide; D003094:Collagen